

AzNETT NEWSLETTER

Mission


The mission of the Neurologic Emergencies Treatment Trials (NETT) Network is to improve outcomes of patients with acute neurologic problems through innovative research focused on the emergent phase of patient care.


Vision

NETT will engage clinicians and providers at the front lines of emergency care to conduct large, simple multicenter clinical trials to answer research questions of clinical importance. The NETT structure will be utilized to achieve economies of scale enabling cost effective, high quality research.



Men are born to succeed, not fail.
Henry David Thoreau





What is community consultation and public disclosure (CC/PD)?

Part of the EFIC (exception from informed consent) process is releasing study information to the community in which the study will be deployed. This allows the community to provide feedback, ask questions, share comments and opt out of inclusion in the study.

Our IRB approved CC/PD for RAMPART includes:

- Newspaper ads/stories
- TV ad
- Random Digit Dialing
- Mass mailings to neurology offices
- Spanish ads in newspaper and TV
- City Council meeting
- Glendale Channel 11 information segment

We gather the feedback and present it to the IRB. A decision is made on whether the trial can deploy based on community feedback.

CLINICAL TRIALS


ALIAS - Albumin in Acute Stroke Trial

Local PI: Bruce Coull, MD

NETT PI: Myron Ginsberg, MD - University of Miami

Primary Objective: To determine whether albumin therapy increases the proportion of acute ischemic stroke patients with favorable outcome compared to placebo therapy at 3 months from randomization.

Status: 38 patients screened with 2 enrolled. Nationwide, there are 135 patients enrolled.




RAMPART - Rapid Anticonvulsant Medication Prior to Arrival Trial

Local PI: Dan Spaite, MD

NETT PI: Robert Silbergleit, MD - University of Michigan

Primary Objective: To determine if the efficacy of intramuscular (IM) midazolam is not inferior to intravenous (IV) lorazepam by a pre-specified clinically unimportant absolute difference in the prehospital treatment of status epilepticus.

Status: 12 patients screened with 10 enrolled. Nationally 148 patients enrolled.




ProTECT - Progesterone for Traumatic Brain Injury: Experimental Clinical Treatment

Local PI: Peter Rhee, MD

NETT PI: David Wright, MD - Emory University

Primary Objective: To determine the effectiveness of intravenous progesterone initiated within 4 hours of injury and administered for 96 hours as compared to placebo at improving functional outcome in patients with moderate to severe traumatic brain injury.

Status: Community consultation/public disclosure plan submitted to IRB. The Protocol was submitted also. We expect enrollment to start in spring 2010.



Do you have an idea for a neurological emergency treatment that you would like studied? Please contact Kurt Denninghoff or Ginny Rizzo. We can assist you in developing a Protocol to run through the NETT. Watch your bright idea change clinical practice and improve the lives of our community members!

Please direct any questions you have regarding AzNETT to:

Principal Investigator, Tucson: Kurt Denninghoff, MD
kdenninghoff@aemrc.arizona.edu, phone 520-626-1551

Research Nurse Coordinator, Tucson: Ginny Rizzo, RN, CCRC
rizzo@aemrc.arizona.edu, phone 520-626-5250

Research Nurse Coordinator, Phoenix: Bruce Barnhart, RN, CEP
bbarnhart@aemrc.arizona.edu, phone 602-827-2140

EMS Coordinator, Phoenix: Willie Haro, CEP
gharo@aemrc.arizona.edu, phone 602-827-2140.

AEMRC Administrative Assistant: Ronnie Benke
rbenke@aemrc.arizona.edu, phone 520-626-8819.

We look forward to working with you!

Happy Halloween



ARIZONA
EMERGENCY MEDICINE
RESEARCH CENTER

